Mizuho analyst Anthony Petrone raised the price target on DexCom (DXCM) to $90 from $78, maintaining an Outperform rating after the company beat fourth-quarter earnings expectations. DexCom reported strong revenue and provided optimistic guidance for 2026, driven by expanded CGM access, new product launches, and margin expansion. The company is positioned for continued growth in the diabetes management and Internet of Medical Things sectors.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Mizuho Raises DexCom (DXCM) Price Target to $90 from $78 After Earnings Beat
Mizuho analyst Anthony Petrone raised the price target on DexCom (DXCM) to $90 from $78, maintaining an Outperform rating after the company beat fourth-quarter earnings expectations. DexCom reported strong revenue and provided optimistic guidance for 2026, driven by expanded CGM access, new product launches, and margin expansion. The company is positioned for continued growth in the diabetes management and Internet of Medical Things sectors.